
A vertical blue bar with five yellow stars, resembling the European Union flag, positioned on the left side of the slide.

EMA activities to implement CVMP recommendations on antimicrobial resistance

**Marienbad, Czech Republic
19-20 May 2009**

Content of the presentation


- 
- A vertical blue bar with a thin black border is positioned on the left side of the slide. It contains five yellow, five-pointed stars arranged vertically, corresponding to the four main bullet points and the sub-points of the second bullet point.
- Role of EMEA
 - Implementation of CVMP strategy and recommendations
 - Direct measures
 - Indirect measures
 - EMEA objectives for the current meeting

Role of EMEA

The role of the EMEA with respect to controlling the risks of AMR arising from the use of veterinary medicines is to foster the development, maintenance and implementation of the CVMP Strategy on Antimicrobials¹ in cooperation with other Community, national and international bodies as appropriate

¹ *CVMP Strategy on Antimicrobials 2006-2010 (EMEA/CVMP/353297/2005) on EMEA website*

Summary of current activities of CVMP in relation to AMR

- 
- A vertical blue bar on the left side of the slide, containing six yellow stars arranged vertically.
- Fluoroquinolones
 - reflection paper
 - referral
 - Cephalosporins
 - Macrolides
 - MRSA
 - SAGAM involvement in MAs
 - Codex Task Force
 - Terms of reference Commission on AMR
 - Coordination of sales of antimicrobials
 - Follow up actions and conclusions from informal CVMPs in Paris and Brno

Implementation of CVMP strategy and recommendations

- Direct
 - Scientific Advisory Group on Antimicrobials (SAGAM)
 - Guidelines
 - Reflection papers
 - Opinions on authorisations
 - Direct for CAPs
 - Indirect for MRP/DCP through referrals



Implementation of CVMP strategy and recommendations

- Indirect
 - Input into Community and International initiatives
 - Commission mandates
 - International guidance
 - Codex
 - OIE/WHO
 - VICH
 - Referrals



Implementation of CVMP strategy and recommendations

- Indirect
 - Communication
 - Recommendations
 - Guidelines
 - Cooperation
 - International
 - Community institutions
 - National Competent authorities
 - Bodies responsible for human AMR



Implementation of CVMP strategy and recommendations

- Indirect
 - Coordination
 - HMA and NCAs
 - Industry
 - Stakeholders
 - Vets
 - Farmers
 - Companion animals owners
 - Pharmacists
 - Wholesalers and distributors



Actions and timescale



Action

CVMP Strategy 2006-2010
HMA Strategy
Commission Mandate
Collection of AM Sales data
Surveillance for zoonotic agents
Surveillance for target pathogens

Actions in the Area of AMR

2008 2009 2010 2011



HMA/EMEA meeting in Marienbad

- Effective coordination essential
 - High level of activity by all involved
 - HMA Action Plan on AMR
 - CVMP Strategy on AMs
 - Increasing political profile of AMR
 - Prudent use requires cooperation to be effective
- Meeting with three main topics
 - Implementation of CVMP recommendations
 - Wider discussion of cooperation in area of prudent use
 - High level discussion of collection of AM sales data



HMA/EMA meeting in Marienbad

- Participants
 - HMA
 - EMA
 - Commission
 - ECDC, EFSA, CRL-AMR
 - Stakeholders
 - IFAH
 - AVC
 - FVE



HMA/EMEA meeting in Marienbad

- Concentration on specific deliverables
 - Recommendations on FQs and Cephalosporins
 - Sales of antimicrobials
- Against a background of an overall strategy
 - CVMP
 - HMA
 - International



HMA/EMEA meeting in Marienbad

- Anticipated outcomes for EMEA
 - Awareness of activities in AMR
 - Agreement on how best HMA and EMEA can cooperate
 - Agreement on role of EMEA in coordinating at EU level NCA activities in collection of AM sales data
 - Views of stakeholders on prudent use and their role in supplying AM sales data

